| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Dept of Pneumonology, Medical School, University of Crete, Iráklion, Depts of 3 Pneumonology and, 6 Histopathology, Sotiria Chest Hospital, and, Depts of 4 Radiology and, 5 Pneumonology, Medical School, University of Athens, and, 7 Dept of Pneumonology, Sismanoglion Hospital, Athens, and, 8 Dept of Pneumonology, Democritus Medical School, University of Thrace, Alexandroúpolis, Greece. 2 Dept of Histopathology, Royal Brompton Hospital, London, UK.
CORRESPONDENCE: D. Bouros, Medical School, Democritus University of Thrace, 68100, Alexandroupolis, Thrace, Greece. Fax: 30 2551076106. E-mail: bouros{at}med.duth.gr
Keywords: Colchicine, idiopathic pulmonary fibrosis, interferon gamma-1b, outcome, survival, treatment
Received: March 20, 2006
Accepted April 5, 2006
Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia is a deadly disease with no effective treatment. The purpose of this randomised prospective multicentric study was to characterise the clinical effects of interferon gamma (IFN-
Fifty consecutive IPF patients were randomised. Patients with mild-to-moderate IPF were eligible for the study if they had histologically proven IPF, or, in the absence of surgical biopsy, fulfilled the European Respiratory Society/American Thoracic Society criteria.
In the intent-to-treat population, five out of 32 (15.6%) IFN-
These data suggest that long-term treatment with interferon gamma 1b may improve survival and outcome in patients with mild-to-moderate idiopathic pulmonary fibrosis. Further studies are needed to verify these results.
) 1b administered subcutaneously thrice weekly versus colchicine for 2 yrs. This study had no pre-specified end-points. -1b patients and seven out of 18 (38.8%) colchicine patients died after a median follow-up period of 25 months Patients treated with IFN- 1b showed a better outcome after 2 yrs of therapy, and fewer symptoms, as assessed using the St George’s Respiratory Questionnaire, after 12 months of therapy. Also, the IFN--1b group exhibited a higher forced vital capacity (percentage of the predicted value) after 24 months of treatment. No significant differences were detected in resting arterial oxygen tension, total lung capacity (% pred), transfer factor of the lung for carbon monoxide (% pred) and high-resolution computed tomographic scoring between the two treatment groups.
This article has been cited by other articles:
|
|
 |
|
  A U Wells, N Hirani, and on behalf of the British Thoracic Society Intersti Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society Thorax, September 1, 2008; 63(Suppl_V): v1 - v58. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini Review: New perspectives in the treatment of idiopathic pulmonary fibrosis Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93. [Abstract] [PDF]
|
|
|
|
 |
|
 C. J. Scotton and R. C. Chambers Molecular Targets in Pulmonary Fibrosis: The Myofibroblast in Focus Chest, October 1, 2007; 132(4): 1311 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Raghu Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches. Eur. Respir. J., September 1, 2006; 28(3): 463 - 465. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
